Statistics from Altmetric.com
Oral standardized frankincense extracts could open a new therapeutic era in treatment of relapsing-remitting multiple sclerosis patients
Over the last 20 years, the treatment landscape of relapsing-remitting multiple sclerosis (RRMS) has impressively changed and new oral first-line agents have been licensed. Indeed, from a complete lack of any treatment, neurologists have gone to drugs that are increasingly effective but which are associated with significant risks that can affect the survival of their patients. Neurologist specialised in the treatment of MS have to expand their medical skills and become familiar with haematological, cardiac, hepatic, renal and endocrine adverse events which were reported with the use of newer treatments now available. Neurologists must also become aware of the risk of opportunistic infections …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.